Inventor · disambiguated record
Remi-Martin Laberge
Also filed as: LABERGE REMI-MARTIN
24 granted patents·17 pending applications·162 citations·filing 2013–2023
96Inventor score
Files withBUCK INST RES AGING20UNITY BIOTECHNOLOGY INC14BUCK INST FOR RES ON AGING2BUCK INSTITUTE FOR RES AND AGING2MAYO FOUND MEDICAL EDUCATION & RES2
Top patents by PatentIndex Score
41 records- 0198US10010546B2Treatment of ophthalmic conditions by selectively removing senescent cells from the eyeBUCK INST RES AGING·Filed 2017·Granted Jul 3, 2018·23 cites·11 claims
- 0297US9849128B2Unit dose of a cis-imidazoline for treating an osteoarthritic joint by removing senescent cellsBUCK INST RES AGING·Filed 2017·Granted Dec 26, 2017·24 cites·15 claims
- 0396US9993472B2Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2BUCK INST RES AGING·Filed 2015·Granted Jun 12, 2018·20 cites·7 claims
- 0496US9980962B2Use of sulfonamide inhibitors of Bcl-2 to treat senescence-associated lung conditions such as pulmonary fibrosis and chronic obstructive pulmonary diseaseBUCK INST RES AGING·Filed 2017·Granted May 29, 2018·6 cites·8 claims
- 0596US9855266B2Treatment for osteoarthritis by intra-articular administration of a cis-imidazolineBUCK INST RES AGING·Filed 2017·Granted Jan 2, 2018·12 cites·14 claims
- 0695US10328073B2Use of sulfonamide inhibitors of BCL-2 and BCL-xL to treat ophthalmic disease by selectively removing senescent cellsUNITY BIOTECHNOLOGY INC·Filed 2018·Granted Jun 25, 2019·9 cites·16 claims
- 0795US10130628B2Treatment of joint painUNITY BIOTECHNOLOGY INC·Filed 2017·Granted Nov 20, 2018·6 cites·8 claims
- 0894US10478432B2Compositions of matter for treatment of ophthalmic conditions by selectively removing senescent cells from the eyeBUCK INST RES AGING·Filed 2018·Granted Nov 19, 2019·7 cites·18 claims
- 0994US9901080B2Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cellsBUCK INST RES AGING·Filed 2016·Granted Feb 27, 2018·16 cites·20 claims
- 1092US10517866B2Removing senescent cells from a mixed cell population or tissue using a phosphoinositide 3-kinase (PI3K) inhibitorUNITY BIOTECHNOLOGY INC·Filed 2018·Granted Dec 31, 2019·5 cites·15 claims
- 1192US10258618B2Treating pulmonary conditions by selectively removing senescent cells from the lung using an intermittent dosing regimenBUCK INST RES AGING·Filed 2018·Granted Apr 16, 2019·5 cites·17 claims
- 1291US10328058B2Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaquesMAYO FOUND MEDICAL EDUCATION & RES·Filed 2017·Granted Jun 25, 2019·5 cites·12 claims
- 1391US10213426B2Method of optimizing conditions for selectively removing a plurality of senescent cells from a tissue or a mixed cell populationBUCK INST RES AGING·Filed 2017·Granted Feb 26, 2019·5 cites·13 claims
- 1490US11351167B2Treating cognitive decline and other neurodegenerative conditions by selectively removing senescent cells from neurological tissueBUCK INST RES AGING·Filed 2019·Granted Jun 7, 2022·1 cites·14 claims
- 1590US10478433B2Unit dose of an aryl sulfonamide that is effective for treating eye disease and averting potential vision lossUNITY BIOTECHNOLOGY INC·Filed 2018·Granted Nov 19, 2019·4 cites·20 claims
- 1690US10413542B2Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders using an inhibitor of Akt kinaseBUCK INST RES AGING·Filed 2018·Granted Sep 17, 2019·4 cites·12 claims
- 1789US10519197B1Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancerUNITY BIOTECHNOLOGY INC·Filed 2019·Granted Dec 31, 2019·3 cites·14 claims
- 1886US9884065B2Inhibiting activity of senescent cells using a glucocorticoidBUCK INST RES AGING·Filed 2016·Granted Feb 6, 2018·5 cites·15 claims
- 1982US12285427B2Treatment of a senescence-associated ocular disease or disorder using a Bcl-xL selective inhibitorBUCK INST RES AGING·Filed 2023·Granted Apr 29, 2025·0 cites·4 claims
- 2082US9901081B2Transgenic mouse for determining the role of senescent cells in cancerBUCK INST RES AGING·Filed 2016·Granted Feb 27, 2018·2 cites·12 claims
- 2179US11980616B2Treating liver disease by selectively eliminating senescent cellsBUCK INST RES AGING·Filed 2020·Granted May 14, 2024·0 cites·23 claims
- 2279US2019343832A1Therapy for removing senescent cells and treating senescence-associated disease using an mdm2 inhibitorUNITY BIOTECHNOLOGY INC·Filed 2019·Application pending·0 cites
- 2378US11963957B2Treating cardiovascular disease by selectively eliminating senescent cellsBUCK INST RES AGING·Filed 2020·Granted Apr 23, 2024·0 cites·24 claims
- 2477US2021030752A1Treating cognitive decline and other neurodegenerative conditions by selectively removing senescent cells from neurological tissueBUCK INST RES AGING·Filed 2020·Application pending·0 cites
- 2572US2022096466A1Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agentsBUCK INSTITUTE FOR RES AND AGING·Filed 2021·Application pending·0 cites
- 2671US2019175623A1Chemical compounds for treating atherosclerosis by stabilizing atherosclerotic plaques or delaying atherogenesisBUCK INST RES AGING·Filed 2018·Application pending·0 cites
- 2769US2020338094A1Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related ConditionsUNITY BIOTECHNOLOGY INC·Filed 2020·Application pending·0 cites
- 2867US2018110787A1Treatment for Idiopathic Pulmonary Fibrosis and Chronic Obstructive Pulmonary DiseaseBUCK INST RES AGING·Filed 2017·Application pending·0 cites
- 2967US2018000816A1Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related ConditionsUNITY BIOTECHNOLOGY INC·Filed 2017·Application pending·0 cites
- 3064US10689416B2Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancerUNITY BIOTECHNOLOGY INC·Filed 2019·Granted Jun 23, 2020·0 cites·10 claims
- 3163US10655144B2Nucleic acid construct with a p16 promoter that causes a prodrug converting enzyme to be expressed specifically in senescent cellsBUCK INST RES AGING·Filed 2018·Granted May 19, 2020·0 cites·10 claims
- 3260US2020354336A9Treatment of Lung Diseases Using Pharmaceutical Agents that Eliminate Senescent CellsUNITY BIOTECHNOLOGY INC·Filed 2018·Application pending·0 cites
- 3359US2024245680A1Methods of Treating Retinal VasculopathiesKIMURA SCOTT·Filed 2022·Application pending·0 cites
- 3458US2019269675A1Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agentsBUCK INSTITUTE FOR RES AND AGING·Filed 2019·Application pending·0 cites
- 3558US2020338097A1Use of a heterocyclic bcl-2 inhibitor for removing senescent cells and treating senescence-associated conditionsUNITY BIOTECHNOLOGY INC·Filed 2020·Application pending·0 cites
- 3651US2018193458A1Compositions and methods for treating senescence-associated diseases and disordersUNITY BIOTECHNOLOGY INC·Filed 2016·Application pending·0 cites
- 3749US2019000846A1Pharmaceutical Products and Drug Combinations for Treating Atherosclerosis by Stabilizing Atherosclerotic Plaques and Promoting Plaque RegressionMAYO FOUND MEDICAL EDUCATION & RES·Filed 2018·Application pending·0 cites
- 3848US2017266211A1Use of a heterocyclic bcl-2 inhibitor for removing senescent cells and treating senescence-associated conditionsUNITY BIOTECHNOLOGY INC·Filed 2017·Application pending·0 cites
- 3946US2020360386A1Inhibitors of HSP90, PI3-Kinase, Proteasome, HDAC, and P97 Pathways for Selective Removal of Senescent Cells in the Treatment of Age Related ConditionsUNITY BIOTECHNOLOGY INC·Filed 2018·Application pending·0 cites
- 4042US2013288981A1Targeting senescent cells and cancer cells by interference with jnk and/or foxo4BUCK INST FOR RES ON AGING·Filed 2013·Application pending·0 cites
- 4137US2013288980A1Targeting senescent and cancer cells for selective killing by interference with foxo4BUCK INST FOR RES ON AGING·Filed 2013·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →